Donna McMenamin is one of thousands of breast cancer patients in the UK caught up in a disagreement over costs between the ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Community event aims to raise awareness and support for local cancer patients through high school senior project ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

In a review of 182 cancer studies, authors failed to report outcome data by sex in 90% of cases, even though men develop ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a positive phase 3 readout. | AstraZeneca and Daiichi Sankyo are gunning to get ...

Daiichi Sankyo’s optimism is driven by the strong performance of Enhertu, with related revenue soaring by 45% YoY to ¥651 billion, accounting for the majority of the company’s overall revenue increase ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic ...